Bullish On Bumble: Analyst Predicts Growth From New Features
Bumble Inc. saw a drop in share price after its IPO, but an analyst upgraded its rating due to promising new products and marketing campaign.
Why Is Coffee Chain Dutch Bros Stock Gaining Today?
Dutch Bros surges as TD Cowen analyst upgrades stock to Buy, citing impressive earnings beat and sales growth. Analyst projects strong performance in 2024 with beverage innovation and loyalty program driving results.
Squarespace To See Whopping 20% Growth Over Medium Term On Pricing Tailwinds: Analyst
Mizuho analyst upgrades Squarespace to Buy, citing growth potential from Google Domains acquisition, pricing tailwinds, and increased domain traffic.
SiTime Stock Skyrockets 30% After Analyst Upgrade
SITM up ~31% on Needham's upgrade to Buy with $130 PT. Beat & raise Q1 results with rebound in customer orders. Visibility improving for strong growth in 2024 and 2025.
Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
EVgo’s Q1 Performance Sparks Optimism, Analyst Upgrades Stock
Cantor Fitzgerald analyst upgrades EVgo to Overweight on solid sales growth and strategic moves. Q1 FY24 sales surge 118.2% YoY, surpassing estimates.
Affirm Holdings Selloff Is ‘Baffling’: Analysts Dive Into Financial Results
Affirm Holdings (AFRM) stock rises after reporting strong fiscal Q3 results amid exciting earnings season. Analysts have mixed takeaways.
Shopify Profitability Remains A Concern, 5 Analysts Offer Commentary On Q1 Earnings
Shopify gross profit margins are expected to contract in the second quarter, one analyst says. The company's first-quarter beat was "modest."
What’s Going On With Micron Tech Stock On Monday?
Analyst upgrades Micron Technology Inc (MU) from Neutral to Outperform, raises price target to $150. Remains bullish on US semiconductor sector.
Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value
Amgen earnings beat estimates, and MariTide's promising Phase 2 results suggest significant differentiation from competitors.